Currently, only three biomarkers are used in routine practice to select patients with advanced stage G/GEJ cancer before administering molecularly targeted therapies: HER2 positivity for trastuzumab and T-DXd treatment, and MSI status and PD-L1 expression for anti-PD-1 treatment. Here, ERBB2 is linked to cancer.